Australian plasma. Global process.
Under the National Fractionation Agreement for Australia in place between the National Blood Authority and CSL Behring, CSL Behring has been investing in new facilities to provide expanded capacity for processing Australia’s growing annual domestic plasma collections.
CSL Behring is transitioning Australia’s human prothrombin complex product to being manufactured within these new, purpose-built manufacturing facilities in Broadmeadows, Victoria.
Australian domestic plasma products will be manufactured in Australia from plasma collected onshore by the Australia Red Cross Lifeblood but will be manufactured using CSL Behring’s innovative global manufacturing processes. As per the current products, the new products will comply with the safety and efficacy requirements set by the Therapeutic Goods Administration.
During the transition to Beriplex® (manufactured from Australian-sourced plasma) there will be a short period where the available Beriplex® will be manufactured from globally-sourced plasma.
